Fampridine

Active substance Fampridine
Domain Neurological disorders
Reason of inclusion in Horizonscan Geneesmiddelen Generic
Main indication Multiple sclerosis

Product

Current proprietary name Fampyra (Biogen)
Mechanism of action Ion channel blocker
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date September 2019
Expected Registration September 2020
Registration phase Registration application pending
Additional comments SPC Fampridine (Biogen) verloopt op 24 juli 2026.

Therapeutic value

Therapeutic value Potential equal value
Duration of treatment Not found

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.